2-(1-piperidinylmethyl)-6-quinolinylamine | 372149-99-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(1-piperidinylmethyl)-6-quinolinylamine
• 英文别名: 6-amino-2-(1-piperidinylmethyl)quinoline；2-(Piperidin-1-ylmethyl)quinolin-6-amine
• CAS: 372149-99-0
• 化学式: C₁₅H₁₉N₃
• 分子量: 241.336
• InChiKey: KHLTXMUSFLOCCS-UHFFFAOYSA-N

物化性质

• 沸点：
  401.9±30.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1-piperidinylmethyl)-6-quinolinylamine 生成 4-(4-Methylphenyl)-N-[2-(1-piperidinylmethyl)-6-quinolinyl]-1-piperidinecarboxamide
  参考文献：
  名称：

  MELANIN CONCENTRATING HORMONE ANTAGONISTS

  摘要：

  公开号：

  EP1285651B1
• 作为产物：
  描述：

  6-硝基-2-(1-哌啶基甲基)喹啉 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 6.0h， 生成 2-(1-piperidinylmethyl)-6-quinolinylamine
  参考文献：
  名称：

  Potent, Selective, and Orally Efficacious Antagonists of Melanin-Concentrating Hormone Receptor 1

  摘要：

  The high expression of MCH in the hypothalamus with the lean hypophagic phenotype coupled with increased resting metabolic rate and resistance to high fat diet-induced obesity of MCH KO mice has spurred considerable efforts to develop small molecule MCHR1 antagonists. Starting from a lead thienopyrimidinone series, structure-activity studies at the 3- and 6-positions of the thienopyrimidinone core afforded potent and selective MCHR1 antagonists with representative examples having suitable pharmacokinetic properties. Based on structure-activity relationships, a structural model for MCHR1 was constructed to explain the binding mode of these antagonists. In general, a good correlation was observed between pK(a)s and activity in the right-hand side of the template, with Asp123 playing an important role in the enhancement of binding affinity. A representative example when evaluated chronically in diet-induced obese mice resulted in good weight loss effects. These antagonists provide a viable lead series in the discovery of new therapies for the treatment of obesity.

  DOI：

  10.1021/jm060572f

文献信息

• NOVEL EGFR MODULATORS AND USES THEREOF
  申请人：ACEA BIOSCIENCES INC.

  公开号：US20140038940A1

  公开（公告）日：2014-02-06

  The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

  本发明涉及某些吡咯并嘧啶衍生物、含有它们的药物组合物以及使用它们的方法，包括治疗肿瘤和与激酶（如EGFR（包括HER）、Alk、PDGFR，但不限于此）途径失调相关的疾病的方法。
• NOVEL PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
  申请人：ACEA BIOSCIENCES INC.

  公开号：US20150210702A1

  公开（公告）日：2015-07-30

  The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

  本发明涉及某些吡咯吡嗪衍生物、包含它们的药物组合物以及使用它们的方法，包括用于治疗增殖障碍和与激酶调节失调相关的其他疾病的方法（例如，但不限于，EGFR（包括HER）、Alk、PDGFR、BLK、BMX/ETK、BTK、FLT3（D835Y）、ITK、JAK1、JAK2、JAK3、TEC和TXK）和/或相应途径的方法。
• Melanin-concentrating hormone antagonist
  申请人：——

  公开号：US20040077628A1

  公开（公告）日：2004-04-22

  A melanin-concentrating hormone antagonist comprising a compound of the formula (I): 1 wherein Ar 1 is a cyclic group which may be substituted; X and Y are the same or different and are a spacer having a main chain of 1 to 6 atoms; Ar is a condensed polycyclic aromatic ring which may be substituted; R 1 and R 2 are the same or different and are hydrogen atom or a hydrocarbon group which may be substituted; or R 1 and R 2 , together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R 2 , together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or R 2 , together with the adjacent nitrogen atom, Y and Ar, may form a condensed ring; or a salt thereof is useful as an agent for preventing or treating obesity, etc.

  一种黑色素浓集激素拮抗剂，包括化合物(I)的一种，其中Ar1是一个可以被取代的环状基团；X和Y相同或不同，是具有1至6个原子的主链间隔物；Ar是一个可以被取代的紧凑多环芳香环；R1和R2相同或不同，是氢原子或可以被取代的碳氢基团；或者R1和R2与相邻的氮原子一起可以形成一个可以被取代的含氮杂环；或者R2与相邻的氮原子和Y一起可以形成一个可以被取代的含氮杂环；或者R2与相邻的氮原子、Y和Ar一起可以形成一个紧凑环；或其盐，可用作预防或治疗肥胖等药物。
• EGFR modulators and uses thereof
  申请人：Acea Biosciences Inc.

  公开号：US10449196B2

  公开（公告）日：2019-10-22

  The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

  本发明涉及某些吡咯并嘧啶衍生物、含有它们的药物组合物以及使用它们的方法，包括治疗与激酶（如表皮生长因子受体（包括 HER）、Alk、表皮生长因子受体，但不限于此）通路失调有关的肿瘤和相关疾病的方法。
• Pyrrolopyrimidine compounds as inhibitors of protein kinases
  申请人：ACEA BIOSCIENCES INC.

  公开号：US10596174B2

  公开（公告）日：2020-03-24

  The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

  本发明涉及某些吡咯并嘧啶衍生物、含有它们的药物组合物以及使用它们的方法，包括治疗增殖障碍和其他与激酶（如但不限于表皮生长因子受体（包括HER）、Alk、表皮生长因子受体、BLK、BMX/ETK、BTK、FLT3(D835Y)、ITK、JAK1、JAK2、JAK3、TEC和TXK）和/或各自通路失调有关的疾病的方法。